GSK (GSK LN) Q4 (GBP): Revenue 8.62bln (exp. 8.42bln), Adj. EPS 0.255 (exp. 0.224), affirms FY26 guidance and 2031 sales outlook

• Vaccine sales 2.29bln (exp. 2.20bln)
• Shingrix revenue 1.01bln (exp. 827mln)

• Expect 2026 turnover growth of between 3-5%; Core operating profit growth of between 7-9%; Core EPS growth of between 7-9%

GSK's Q4 earnings surpassed expectations on both revenue and adjusted EPS, suggesting robust demand, particularly in vaccine sales and Shingrix. By affirming their FY26 guidance, the company indicates confidence in continuing growth, which could positively influence sentiment in the pharmaceuticals sector and bolster the stock's performance in the near term.